Clinical Trials Arena on MSN10 天
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
The Pharma Letter5 天
The week in pharma: action, reaction and insight – week to March 21
Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...
MPR10 天
Eneboparatide Shows Promise in Chronic Hypoparathyroidism
Eneboparatide is an investigational parathyroid hormone (PTH) receptor 1 agonist. By binding to a specific conformation of the PTH receptor 1, eneboparatide is expected to restore PTH function and ...
The Pharma Letter11 天
Eneboparatide met primary Phase III endpoint, says AstraZeneca
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
PipelineReview.com11 天
Eneboparatide met primary endpoint of normalising serum calcium in adults with ...
LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...
pharmaphorum1 天
JPM kicks off with takeovers by J&J, Novartis, and MSD
Merck KGaA spin-out Calypso said that Novartis’ involvement ... plus an option on two other drug targets, and has a combined potential value of up to $4.165 billion for Argo, plus royalties ...